RhythmOne sees improvement despite lower revenues

Revenues would be at least US$80mlnin in the six months to September said the former Blinkx

Picture of digital marketing poster
Profitability picking up said former Blinkx

RhythmOne PLC (LON:RTHM)  said its performance had improved in a number of areas over the past six months though sales continued to decline.

Revenues would be at least US$80mlnin in the six months to September said the former Blinkx, compared to US$91.4mln a year ago.

Of that, 80% came from mobile, video and programmatic products with at least US$55mln from programmatic a 45% improvement year-on-year.

Programmatic marketing uses an automated software process digitally to place an advert or campaign.

Underlying losses [EBITDA] will be US$2.9mln compared to US$6.84mln a year ago.

“Importantly, the company achieved increasing profitability on an adjusted EBITDA basis in each of the last two months of the period, significantly ahead of internal estimates,” said RhythymOne.

“Total programmatic transaction volume grew by over 85% year-on-year, with notable increases in quality.”

"Within a year, the team has successfully built an industry-leading, programmatic platform, which currently ranks #4 in size and #3 in quality, as measured by comScore and Pixalate, respectively,” said Brian Mukherjee, chief executive.

“We have set the stage for both top-line revenue growth and a return to full year profitability in FY2017," he added.

Quick facts: RhythmOne

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

3 hours, 16 minutes ago

2 min read